EGFR and neoplasm: TNBC cell line MDA-MB-231 was subcutaneously injected into the flank region of mice and when tumor volume reached 50–100 mm3, anti-EGFR/PD-L1 BsAbs, cetuximab, atezolizumab or saline was injected in tumor-bearing mice.